Drug updates and approvals: 2017 in review. Issue 12 (15th December 2017)

• Record Type: Journal Article
• Authors: Mospan, Geoffrey; Mospan, Cortney; Vance, Shayna; Bradshaw, Alyssa; Meosky, Kalyn; Bowles, Kirklin
• Is Part Of: Nurse practitioner. Volume 42:Issue 12(2017:Dec.)
• Publication Date: 2017-12-15
• Subjects: 2017 -- atopic dermatitis -- eczema -- FDA -- FDA approved -- new drugs -- Parkinson disease -- plaque psoriasis -- rheumatoid arthritis -- rosacea -- type 2 diabetes mellitus -- T2DM; Nursing -- Periodicals; Nurse practitioners -- Periodicals; 610.73
• DOI: 10.1097/01.NPR.0000526760.22854.f1
• Languages: English
• ISSNs: 0361-1817

Abstract

Abstract : Abstract: In 2017, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara). Abstract : In 2017, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara).